Contact Details
University Links
- Position
- Clinical Professor
- Department
- Department of Medicine (Christchurch)
- Research summary
- Liver disease
Research
Dr Stedman's field of research is liver disease and pharmacology, focusing on hepatitis C and autoimmune liver diseases. Her published papers in hepatitis C epidemiology have influenced global understanding of chronic hepatitis C epidemiology including government and Ministry of Health understanding and approach to hepatitis C treatment strategies.
Publications
Polaris Observatory Collaborators, including Stedman, C. A. M. (2025). Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies. Journal of Hepatology, 83(2), 329-347. doi: 10.1016/j.jhep.2025.01.013 Journal - Research Article
Benson-Pope, S., Stedman, C., & Ngu, J. (2025). Epidemiology of primary sclerosing cholangitis in Canterbury, New Zealand: A population-based study. Journal of Hepatology, 82(Suppl. 1), THU-358-YI. doi: 10.1016/S0168-8278(25)01029-3 Conference Contribution - Published proceedings: Abstract
Tian, C., Stedman, C., Burt, M., Barclay, M., & Ngu, J. (2025). Efficacy of tioguanine and mycophenolate mofetil as second-line immunosuppressive treatment in autoimmune hepatitis. Journal of Hepatology, 82(Suppl. 1), THU-289. doi: 10.1016/S0168-8278(25)00973-0 Conference Contribution - Published proceedings: Abstract
Tiong, H. T., Upton, A., Lockie, A., Moore, K., & Stedman, C. A. M. (2025). Hepatitis C virus seroprevalence in defined populations in New Zealand: Data from a general practice-based screening programme. New Zealand Medical Journal/Te ara tika o te hauora hapori, 138(1610), 52-59. Retrieved from https://www.nzmj.org.nz/ Journal - Research Article
Kaj‐Carbaidwala, B., Fevery, J., Adler, D. G., Bergquist, A., de Ridder, L., Deneau, M., … Stedman, C. A. M., … Lennerz, J. K. (2025). Determining the time to cholangiocarcinoma in pediatric-onset PSC-IBD [Short communication]. Journal of Pediatric Gastroenterology & Nutrition, 80(3), 450-454. doi: 10.1002/jpn3.12443 Journal - Research Other
2025
Journal - Research Article
Polaris Observatory Collaborators, including Stedman, C. A. M. (2025). Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies. Journal of Hepatology, 83(2), 329-347. doi: 10.1016/j.jhep.2025.01.013
Tiong, H. T., Upton, A., Lockie, A., Moore, K., & Stedman, C. A. M. (2025). Hepatitis C virus seroprevalence in defined populations in New Zealand: Data from a general practice-based screening programme. New Zealand Medical Journal/Te ara tika o te hauora hapori, 138(1610), 52-59. Retrieved from https://www.nzmj.org.nz/
Wong, Y. J., Chen, V. L., Abdulhamid, A., Tosetti, G., Navadurong, H., Kaewdech, A., … Stedman, C. A. M., … Abraldes, J. G. (2025). Comparing serial and current liver stiffness measurements to predict decompensation in compensated advanced chronic liver disease patients. Hepatology, 81, 523-531. doi: 10.1097/HEP.0000000000000891
Journal - Research Other
Kaj‐Carbaidwala, B., Fevery, J., Adler, D. G., Bergquist, A., de Ridder, L., Deneau, M., … Stedman, C. A. M., … Lennerz, J. K. (2025). Determining the time to cholangiocarcinoma in pediatric-onset PSC-IBD [Short communication]. Journal of Pediatric Gastroenterology & Nutrition, 80(3), 450-454. doi: 10.1002/jpn3.12443
Conference Contribution - Published proceedings: Abstract
Benson-Pope, S., Stedman, C., & Ngu, J. (2025). Epidemiology of primary sclerosing cholangitis in Canterbury, New Zealand: A population-based study. Journal of Hepatology, 82(Suppl. 1), THU-358-YI. doi: 10.1016/S0168-8278(25)01029-3
Tian, C., Stedman, C., Burt, M., Barclay, M., & Ngu, J. (2025). Efficacy of tioguanine and mycophenolate mofetil as second-line immunosuppressive treatment in autoimmune hepatitis. Journal of Hepatology, 82(Suppl. 1), THU-289. doi: 10.1016/S0168-8278(25)00973-0
2024
Journal - Research Article
Falvey, J., Stedman, C. M., Dunn, J., Sies, C., & Levin, S. (2024). Faecal immunochemical test (FIT) based prioritisation of new patient symptomatic cases referred for colorectal investigation. New Zealand Medical Journal/Te ara tika o te hauora hapori, 137(1602), 102-110. Retrieved from https://journal.nzma.org.nz/
The Polaris Observatory HCV Collaborators, including Stedman, C. A. (2024). Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: A modelling study. Lancet Gastroenterology & Hepatology, 7(5), 396-415. doi: 10.1016/s2468-1253(21)00472-6
2023
Journal - Research Article
Cheng, Q., Cunningham, E. B., Shih, S., Amin, J., Bruneau, J., Artenie, A. A., … Stedman, C., … on behalf of the SIMPLIFY and D3FEAT Study Groups. (2023). Patient reported outcomes during and following HCV direct-acting antiviral treatment among people who inject drugs. Value in Health, 26(6), 883-892. doi: 10.1016/j.jval.2022.12.016
Other Research Output
Stedman, C. (2023, May). Hepatitis C and liver disease: The journey to cure and eliminate. University of Otago, Christchurch, New Zealand. [Inaugural Professorial Lecture].
2022
Journal - Research Other
Walter, T., Connor, S., Stedman, C., & Doogue, M. (2022). A case of acute necrotising pancreatitis following the second dose of Pfizer-BioNTech COVID-19 mRNA vaccine. British Journal of Clinical Pharmacology, 88, 1385-1386. doi: 10.1111/bcp.15039
2021
Journal - Research Article
Lamba, M., Ngu, J. H., & Stedman, C. A. M. (2021). Trends in incidence of autoimmune liver diseases and increasing incidence of autoimmune hepatitis. Clinical Gastroenterology & Hepatology, 19(3), 573-579.e1. doi: 10.1016/j.cgh.2020.05.061
Cunningham, E. B., Hajarizadeh, B., Amin, J., Hellard, M., Bruneau, J., Felderhof, J. J., … Stedman, C., … on behalf of the SIMPLIFY and D3FEAT Study Groups. (2021). Reinfection following successful direct-acting antiviral therapy for hepatitis C infection among people who inject drugs. Clinical Infectious Diseases, 72(8), 1392-1400. doi: 10.1093/cid/ciaa253
2020
Journal - Research Article
Artenie, A. A., Cunningham, E. B., Dore, G. J., Conway, B., Dalgard, O., Powis, J., … Stedman, C., … Grebely, J. (2020). Patterns of drug, alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies: An international study. Clinical Infectious Diseases, 70(11), 2369-2376. doi: 10.1093/cid/ciz633
Wade, A. J., Doyle, J. S., Gane, E., Stedman, C., Draper, B., Iser, D., … Hellard, M. E. (2020). Outcomes of treatment for hepatitis C in primary care compared to hospital-based care: A randomized, controlled trial in people who inject drugs. Clinical Infectious Diseases, 70(9), 1900-1906. doi: 10.1093/cid/ciz546
Conference Contribution - Published proceedings: Abstract
Mules, T., Stedman, C. A., Ding, S., Burt, M., Gearry, R., Chalmers-Watson, T., Falvey, J., Chapman, B., Barclay, M. L., Lim, G., … Ngu, J. H. (2020). The ABC score accurately predicts mortality in hospitalized patients that develop upper gastrointestinal bleeding. Gastrointestinal Endoscopy, 91(6, Suppl.), (pp. AB590-AB591). doi: 10.1016/j.gie.2020.03.3668
Conference Contribution - Verbal presentation and other Conference outputs
Cunningham, E., Hajarizadeh, B., Amin, J., Hellard, M., Bruneau, J., Feld, J. J., … Stedman, C., … Grebely, J. (2020, March). Reinfection following successful direct-acting antiviral therapy for hepatitis C infection among people who inject drugs. Verbal presentation at the Canadian Liver Meeting (CLM), Montreal, Canada.
Stedman, C. (2020, August). The first and last Hep C elimination strategy in NZ. Plenary presentation at the South General Practice Conference & Medical Exhibition (GP CME), Christchurch, New Zealand.
2019
Journal - Research Article
Gane, E., Poordad, F., Zadeikis, N., Valdes, J., Lin, C.-W., Liu, W., … Stedman, C., … Mensa, F. J. (2019). Safety and pharmacokinetics of glecaprevir/pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infections and compensated liver disease. Clinical Infectious Diseases, 69(10), 1657-1664. doi: 10.1093/cid/ciz022
Journal - Research Other
Tharayil, V. S., Chalmers-Watson, T., Cole, D., & Stedman, C. (2019). Oesophageal tuberculosis: A rare cause of dysphagia. Annals of Clinical Case Reports, 4, 1597. [Case Study].
Conference Contribution - Published proceedings: Abstract
Lamba, M., De Roza, M. A., Stedman, C. A., Lum, H. M. J., Goh, G. B., & Ngu, J. H. (2019). Autoimmune markers in NASH predict clinical outcome: Multicentre observational study. Gastroenterology, 156(6, Suppl.), (pp. S-1216). doi: 10.1016/S0016-5085(19)40024-3
Morahan, M.-C., Coberger, E., Stedman, C., & Doogue, M. (2019). Validity and reliability of clinical resources on adverse effects of medicines: Drug-induced liver injury. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Population Approach Group of Australia and New Zealand (PAGANZ) Joint Scientific Meeting: Shared Horizons: Optimizing Drug Response to Improve Patient Outcomes. (pp. 28). Retrieved from https://www.asceptasm.com
Grebely, J., Cunningham, E. B., Dalgard, O., Hajarizadeh, B., Conway, B., Powis, J., … Stedman, C., … Dore, G. (2019). Reinfection following successful HCV DAA therapy among people with recent injecting drug use. Journal of Hepatology, 70(1, Suppl.), (pp. e732-e733). doi: 10.1016/S0168-8278(19)30205-3
Conference Contribution - Poster Presentation (not in published proceedings)
Cunningham, E. B., Grebely, J., Dalgard, O., Hajarizadeh, B., Conway, B., Powis, J., … Stedman, C., … Dore, G. J. (2019, August). Reinfection following successful HCV DAA therapy among people with recent injecting drug use or current opioid substitution therapy. Poster session presented at the 2nd Australasian Viral Hepatitis Elimination Conference (AVHEC), Sydney, Australia.
2018
Journal - Research Article
Grebely, J., Conway, B., Cunningham, E. B., Fraser, C., Moriggia, A., Gane, E., Stedman, C., … on behalf of the D3FEAT Study Group. (2018). Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. International Journal of Drug Policy, 62, 94-103. doi: 10.1016/j.drugpo.2018.10.004
Gane, E. J., Stedman, C. A., Schwabe, C., Vijgen, L., Chanda, S., Kakuda, T. N., … McClure, M. W. (2018). Short duration AL-335, odalasvir, with or without simeprevir, in patients with HCV GT1 or 3 infection without cirrhosis. Hepatology, 68(6), 2145-2157. doi: 10.1002/hep.30126
Polaris Observatory Collaborators, including Stedman, C. (2018). Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study. Lancet Gastroenterology & Hepatology, 3(6), 383-403. doi: 10.1016/S2468-1253(18)30056-6
Zeuzem, S., Foster, G. R., Wang, S., Asatryan, A., Gane, E., Feld, J. J., … Stedman, C. A., … Mensa, F. J. (2018). Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. New England Journal of Medicine, 378(4), 354-369. doi: 10.1056/NEJMoa1702417
Meijer, B., van Everdingen, C. K., Ramsoekh, D., Stedman, C., Frampton, C. M. A., Mulder, C. J. J., … Gearry, R. B. (2018). Transient elastography to assess liver stiffness in patients with inflammatory bowel disease. Digestive & Liver Disease, 50(1), 48-53. doi: 10.1016/j.dld.2017.09.128
Journal - Research Other
Wade, A. J., Doyle, J. S., Gane, E., Stedman, C., Draper, B., Iser, D., … Hellard, M. E. (2018). Community-based provision of direct-acting antiviral therapy for hepatitis C: Study protocol and challenges of a randomized controlled trial. Trials, 19, 383. doi: 10.1186/s13063-018-2768-3
Conference Contribution - Published proceedings: Abstract
Lamba, M., Daker, C., Metcalf, S., Burt, M., Stedman, C., Chapman, B., & Ngu, J. (2018). Are patients with chronic hepatitis B receiving recommended HCC surveillance? Proceedings of the New Zealand Society of Gastroenterology and the NZNO Gastroenterology Nurses' College Annual Scientific Meeting. Retrieved from http://gastro2018.co.nz
Stedman, C. (2018). Screening for HCC: Who, how and how often? Proceedings of the New Zealand Society of Gastroenterology and the NZNO Gastroenterology Nurses' College Annual Scientific Meeting. Retrieved from http://gastro2018.co.nz
Lamba, M., Stedman, C., & Ngu, J. (2018). Incidence of autoimmune hepatitis is increasing, while primary biliary cholangitis and primary sclerosing cholangitis have remained unchanged: A population-based study. Journal of Hepatology, 68(Suppl. 1), (pp. S231). doi: 10.1016/S0168-8278(18)30677-9
Wade, A., Doyle, J., Gane, E. J., Stedman, C. A., Draper, B., Iser, D., … Hellard, M. E. (2018). Providing direct acting antiviral therapy in primary care increases treatment uptake: Results from the Prime Study, a randomized controlled trial, comparing the hepatitis C care cascade in primary care versus tertiary care. Hepatology, 68(Suppl. 1), (pp. 302A-303A). doi: 10.1002/hep.30257
Grebely, J., Conway, B., Fraser, C., Moriggia, A., Cunningham, E., Gane, E., Stedman, C., … Dore, G. J. (2018). Paritaprevir/ritonavir/ombitasvir, dasabuvir + ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving OST: The D3FEAT study. Canadian Liver Journal, 1(1), (pp. 45-46). [Abstract]
Lamba, M., Stedman, C., & Ngu, J. (2018). Autoantibody-negative autoimmune hepatitis presents more commonly with advanced fibrosis or cirrhosis. Journal of Hepatology, 68(Suppl. 1), (pp. S231). doi: 10.1016/S0168-8278(18)30678-0
Wade, A., Doyle, J., Gane, E., Stedman, C., Draper, B., Iser, D., … Hellard, M. (2018). Preliminary analysis of the Prime Study: A randomized controlled trial comparing the hepatitis C care cascade in primary care vs. tertiary care. Journal of Hepatology, 68(Suppl. 1), (pp. S315). doi: 10.1016/S0168-8278(18)30848-1
Lamba, M., Stedman, C., & Ngu, J. (2018). Plasma cells in non-alcoholic steatohepatitis correlates with disease activity. Journal of Hepatology, 68(Suppl. 1), (pp. S830). doi: 10.1016/S0168-8278(18)31935-4
Conference Contribution - Verbal presentation and other Conference outputs
Cunningham, E. B., Grebely, J., Dalgard, O., Hajarizadeh, B., Conway, B., Powis, J., … Stedman, C., … on behalf of the SIMPLIFY and D3FEAT Study Groups. (2018, September). Reinfection following successful HCV DAA therapy among people with recent injecting drug use: The SIMPLIFY and D3FEAT studies. Verbal presentation at the 7th International Symposium on Hepatitis Care in Substance Users (INHSU), Lisbon, Portugal.
Cunningham, E. B., Grebely, J., Dalgard, O., Hajarizadeh, B., Conway, B., Powis, J., … Stedman, C., … on behalf of the SIMPLIFY and D3FEAT Study Groups. (2018, August). Recurrent viraemia following successful HCV DAA therapy among people with recent injecting drug use: The SIMPLIFY and D3FEAT studies. Verbal presentation at the 11th Australasian Viral Hepatitis Conference (ABC), Adelaide, Australia.
Stedman, C. (2018, August). Hepatitis C: How to find and treat patients in primary care. Verbal presentation at the 9th South General Practice Conference & Medical Exhibition (GP CME), Christchurch, New Zealand.
Working Paper; Discussion Paper; Technical Report
Hepatitis C Summit Steering Committee, including Stedman, C. (2018). Eliminating hepatitis C in New Zealand Green Paper: The urgent need to develop a hepatitis C National Action Plan. 13p. Retrieved from https://researchspace.auckland.ac.nz/handle/2292/45012
2017
Journal - Research Article
Gane, E. J., Metivier, S., Nahass, R., Ryan, M., Stedman, C. A., Svarovskaia, E. S., … Lawitz, E. (2017). The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment. Hepatology Communications, 1(6), 538-549. doi: 10.1002/hep4.1060
The Polaris Observatory HCV Collaborators, including Brunton, C. R., & Stedman, C. (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterology & Hepatology, 2(3), 161-176. doi: 10.1016/S2468-1253(16)30181-9
Gane, E. J., Shiffman, M. L., Etzkorn, K., Morelli, G., Stedman, C. A. M., Davis, M. N., … and the GS-US-342-1553 Investigators. (2017). Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen. Hepatology, 66(4), 1083-1089. doi: 10.1002/hep.29256
Jacobson, I. M., Lawitz, E., Gane, E. J., Willems, B. E., Ruane, P. J., Nahass, R. G., … Stedman, C. A. M., … Foster, G. R. (2017). Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir In patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology, 153(1), 113-122. doi: 10.1053/j.gastro.2017.03.047
Gane, E., Stedman, C., Dole, K., Chen, J., Meyers, C. D., Wiedmann, B., … Colvin, R. A. (2017). A diacylglycerol transferase 1 inhibitor is a potent hepatitis C antiviral in vitro but not in patients in a randomized clinical trial. ACS Infectious Diseases, 3(2), 144-151. doi: 10.1021/acsinfecdis.6b00138
Gane, E. J., Hyland, R. H., Yang, Y., Svarovskaia, E., Stamm, L. M., Brainard, D. M., … Stedman, C. A. M. (2017). Efficacy of ledipasvir plus sofosbuvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2 infection. Gastroenterology, 152(6), 1366-1371. doi: 10.1053/j.gastro.2017.01.017
Journal - Research Other
Ngu, J. H., Gearry, R. B., & Stedman, C. A. M. (2017). Autoimmune hepatitis in the East and the West. Inflammatory Intestinal Diseases, 1(4), 147-149. doi: 10.1159/000455177
Conference Contribution - Published proceedings: Abstract
Lamba, M., Stedman, C., & Ngu, J. (2017). Plasma cells in non-alcoholic steatohepatitis correlates with disease severity: The Canterbury AiLD project. Proceedings of the New Zealand Society of Gastroenterology and the NZNO Gastroenterology Nurses' College Annual Scientific Meeting. 38. Retrieved from http://gastro2017.co.nz
Lamba, M., Stedman, C., & Ngu, J. (2017). Sero-negative autoimmune hepatitis presents more commonly with advanced fibrosis or cirrhosis at diagnosis: The Canterbury AiLD project. Proceedings of the New Zealand Society of Gastroenterology and the NZNO Gastroenterology Nurses' College Annual Scientific Meeting. 39. Retrieved from http://gastro2017.co.nz
Lamba, M., Stedman, C., & Ngu, J. (2017). Increasing incidence of autoimmune hepatitis: Results from the Canterbury AiLD project. Proceedings of the New Zealand Society of Gastroenterology and the NZNO Gastroenterology Nurses' College Annual Scientific Meeting. 35. Retrieved from http://gastro2017.co.nz
Gane, E., Poordad, F., Valdes, J. M., Lin, C.-W., Liu, W., Asatryan, A., … Stedman, C. A., … Mensa, F. (2017). Pharmacokinetics and safety of glecaprevir/pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infection and compensated cirrhosis: An integrated analysis. Gastroenterology, 152(5, Suppl. 1), (pp. S1089). doi: 10.1016/S0016-5085(17)33669-7
Lamba, M., Giles, H., & Stedman, C. (2017). HCC surveillance in patients with advanced fibrosis: Christchurch experience. Liver Cancer, 6(Suppl.), (pp. 40). [Abstract]
Gane, E. J., Poordad, F., Zadeikis, N., Valdes, J. M., Lin, C.-W., Liu, W., … Stedman, C. A., … Mensa, F. J. (2017). Efficacy, safety, and pharmacokinetics of glecaprevir/pibrentasvir in adults with chronic genotype 1-6 Hepatitis C Virus infection and compensated cirrhosis: An integrated analysis. Hepatology, 66(Suppl. 1), (pp. 44A). doi: 10.1002/hep.29510
Gane, E., Stedman, C., McClure, M., Apelian, D., Westland, C., Vuong, J., … Fry, J. (2017). Short duration treatment with AL-335 and odalasvir, with or without simeprevir, in treatment naive patients with hepatitis C infection with or without cirrhosis. Journal of Hepatology, 66(Suppl. 1), (pp. S82). doi: 10.1016/S0168-8278(17)30429-4
Gane, E., Poordad, F., Valdes, J., Lin, C.-W., Liu, W., Asatryan, A., … Stedman, C., … Mensa, F. (2017). Pharmacokinetics and safety of glecaprevir/pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infection and compensated cirrhosis: An integrated analysis. Journal of Hepatology, 66(Suppl. 1), (pp. S306). doi: 10.1016/S0168-8278(17)30930-3
Foster, G. R., Gane, E., Asatryan, A., Asselah, T., Ruane, P. J., Pol, S., … Stedman, C. A., … Mensa, F. (2017). ENDURANCE-3: Safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naive HCV genotype 3-infected patients without cirrhosis. Journal of Hepatology, 66(Suppl. 1), (pp. S33). doi: 10.1016/S0168-8278(17)30326-4
Conference Contribution - Verbal presentation and other Conference outputs
Conway, B., Grebely, J., Fraser, C., Moriggia, A., Cunningham, E. B., Gane, E., Stedman, C., … on behalf of the D3FEAT Study Group. (2017, September). Paritaprevir/ritonavir/ombitasvir, dasabuvir ± ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving OST: D3FEAT study. Verbal presentation at the 6th International Symposium on Hepatitis Care in Substance Users (INHSU), New York, USA.
Stedman, C. (2017, June). Autoimmune hepatitis: East and West. Invited presentation at the 1st Xixi International Forum on Gasteroenterology and Liver Diseases & Infectious Diseases, Hangzhou, China.
Stedman, C. (2017, August). Hepatitis C: Cure in the community. Verbal presentation at the 8th South General Practice Conference & Medical Exhibition (GP CME), Christchurch, New Zealand.
Stedman, C., Gearry, R., & Lim, G. (2017, August). Gastroenterology: Basics and beyond. Workshop presentation at the 8th South General Practice Conference & Medical Exhibition (GP CME), Christchurch, New Zealand.
2016
Journal - Research Article
Gane, E. J., Kowdley, K. V., Pound, D., Stedman, C. A. M., Davis, M., Etzkorn, K., … Nguyen, M. H. (2016). Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with hepatitis C virus genotype 2, 3, 4, or 6 infections in an open-label, phase 2 trial. Gastroenterology, 151(5), 902-909. doi: 10.1053/j.gastro.2016.07.038
Gane, E. J., Schwabe, C., Hyland, R. H., Yang, Y., Svarovskaia, E., Stamm, L. M., … Stedman, C. A. (2016). Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3/4A protease inhibitor GS-9857 in treatment-naïve or previously treated patients with HCV genotype 1 or 3 infections. Gastroenterology, 151(3), 448-456. doi: 10.1053/j.gastro.2016.05.021
Gane, E. J., Rouzier, R., Hassanein, T., Stedman, C. A., Mazur, W., Kupcova, V., … Thommes, J. (2016). Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis. Hepatology International, 10(3), 478-487. doi: 10.1007/s12072-015-9699-9
Stedman, C. A. M., Hyland, R. H., Ding, X., Pang, P. S., McHutchison, J. G., & Gane, E. J. (2016). Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection. Haemophilia, 22(2), 214. doi: 10.1111/hae.12791
Journal - Professional & Other Non-Research Articles
Gane, E., & Stedman, C. (2016). New Zealand Society of Gastroenterology HCV Treatment Guidelines. NZSG Guidelines. Retrieved from http://www.nzsg.org.nz/
Conference Contribution - Published proceedings: Abstract
Ngu, J. H., Koay, D. S., Salazar, E., Gearry, R. B., & Stedman, C. A. (2016). Phenotypes of autoimmune hepatitis (AIH) in the West and the East: Comparison of AIH patients in Christchurch and Singapore. Gastroenterology, 150(4, Suppl. 1), (pp. S1075). doi: 10.1016/S0016-5085(16)33625-3
Iser, D., Lawitz, E. J., Ruane, P., Stedman, C., Foster, G., Mir, H. M., … Schwabe, C. (2016). Long-term follow-up of patients with chronic HCV infection following treatment with direct acting antiviral regimens: Maintenance of SVR, persistence of resistance mutations, and clinical outcomes. Journal of Gastroenterology & Hepatology, 31(Suppl. 2), (pp. 74-75). doi: 10.1111/jgh.13519
Galhenage, S., Gane, E. J., Shiffman, M. L., Etzkorn, K., Morelli, G., Stedman, C., … Sulkowski, M. (2016). Sofosbuvir/velpatasvir with ribavirin is effective retreatment for patients who failed NSSA regimens. Journal of Gastroenterology & Hepatology, 31(Suppl. 2), (pp. 71). doi: 10.1111/jgh.13519
Hassanein, T. I., Wyles, D. L., Wang, S., Kwo, P. Y., Shiffman, M. L., Younes, Z., … Stedman, C. A., … Mensa, F. J. (2016). Glecaprevir/pibrentasvir demonstrates high SVR rates in patients with HCV genotype 2, 4, 5, or 6 infection without cirrhosis following an 8-week treatment duration (SURVEYOR-II, Part 4). Hepatology, 64(6), (pp. 1128A). doi: 10.1002/hep.28909
Jacobson, I. M., Asselah, T., Nahass, R., Bhandari, B. R., Tran, A., Hyland, R. H., … Stedman, C. A., … Gane, E. J. (2016). A randomised phase 3 trial of sofosbuvir/velpatasvir/vaxiloprevir for 8 weeks compared to sofosbuvir/velpatasvir for 12 weeks in DAA-naïve genotype 1-6 HCV-infected patients: The POLARIS-2 study. Hepatology, 64(6), (pp. 1126A). doi: 10.1002/hep.28909
Foster, G. R., Zeuzem, S., Gane, E. J., Stedman, C. A., Feld, J. J., Mangia, A., … Pianko, S. (2016). Sofosbuvir-based all-oral regimens for patients with chronic Hepatitis C genotype 3 infection: Integrated analysis of five clinical studies. Hepatology, 64(Suppl. 1), (pp. 955A-956A). doi: 10.1002/hep.28800
Kim, N., Gao, W., Glasgow, X. S., Arrington, L., Crumley, T., Temam, M. F., … Stedman, C., … Marcantonio, E. E. (2016). MK-3682, a HCV NS5B inhibitor with a broad spectrum of HCV genotypic activity, demonstrates potent antiviral activity in genotypes -1, -2, and -3 HCV-infected patients. Reviews in Antiviral Therapy & Infectious Diseases, 6, (pp. 17). Retrieved from http://www.infectiousdiseasesonline.com/abstract-book/
Stedman, C., Workowski, K., Yang, J. C., Natha, M., Abramov, F., Brainard, D. M., … Reddy, K. R. (2016). An integrated safety and efficacy analysis of sofosbuvir-based regimines in HCV-infected patients with hereditary bleeding disorders. Haemophilia, 22(Suppl. 4), (pp. 22). doi: 10.1111/hae.12980
Reddy, K. R., Stedman, C., Workowski, K., Yang, J. C., Stamm, L. M., Lin, M., … Walsh, C. (2016). An integrated safety and efficacy analysis of sofosbuvir-based regimens in patients with hereditary bleeding disorders. Journal of Hepatology, 64(2, Suppl.), (pp. S783). [Abstract]
Gane, E. J., Nguyen, M., Kwo, P., Kowdley, K., Reau, N., Jacobson, I., … Stedman, C., & Lawitz, E. (2016). Short duration treatment with sofosbuvir/velpatasvir plus GS-9857 in treatment-naive genotype 1-6 HCV-infected patients with or without cirrhosis. Journal of Hepatology, 64(2, Suppl.), (pp. S758-759). [Abstract]
Lawitz, E. J., Ruane, P., Stedman, C., Foster, G., Hyland, R. H., Coogan, S., … Schwabe, C. (2016). Long-term follow-up of patients with chronic HCV infection following treatment with direct acting antiviral regimens: Maintenance of SVR, persistence of resistance mutations and clinical outcomes. Journal of Hepatology, 64(2, Suppl.), (pp. S612-S613). [Abstract]
Gane, E., Svarovskaia, E. S., Dvory-Sobol, H., Hyland, R. H., Stamm, L. M., Brainard, D. M., … Stedman, C. A. (2016). Resistance analysis of genotype 1 or 3 HCV-infected patients treated with sofosbuvir/velpatasvir+GS-9857 fo r6 or 8 weeks. Journal of Hepatology, 64(2, Suppl.), (pp. S401-S402). [Abstract]
Gane, E. J., Shiffman, M. L., Etzkorn, K., Morelli, G., Stedman, C., Davis, M. N., … Sulkowski, M. (2016). Sofosbuvir/velpatasvir in combination with ribavirin for 24 weeks is effective retreatment for patients who failed prior NS5A containing DAA regimens: Results of the GS-US-342-1553 study. Journal of Hepatology, 64(2, Suppl.), (pp. S147-S148). [Abstract]
Conference Contribution - Verbal presentation and other Conference outputs
Stedman, C. (2016, November). DILI. Verbal presentation at the New Zealand Society of Gastroenterology & New Zealand Nurses Organisation (NZNO) Gastroenterology Nurses Section Annual Scientific Meeting, Hamilton, New Zealand.
Lamba, M., Giles, H., & Stedman, C. (2016, November). HCC surveillance in patients with advanced fibrosis: Christchurch experience. Verbal presentation at the New Zealand Society of Gastroenterology & New Zealand Nurses Organisation (NZNO) Gastroenterology Nurses Section Annual Scientific Meeting, Hamilton, New Zealand.
Reau, N., Mangia, A., Roberts, S. K., Pianko, S., Thompson, A. J., Cooper, C., … Stedman, C., … Foster, G. (2016, March). Sofosbuvir/velpatasvir for 12 weeks versus sofosbuvir+ribavirin for 24 weeks in GT 3 HCV patients: The Phase 3 ASTRAL-3 Study. Verbal presentation at the International Conference on Viral Hepatitis (ICVH), San Francisco, USA.
Rustgi, V., Kohli, A., Abergel, A., Stedman, C., Asselah, T., Mir, H., … Gane, E. (2016, March). Ledipasvir/sofosbuvir with or without ribavirin for the treatment of patients with genotype 2-6 chronic HCV infection. Verbal presentation at the International Conference on Viral Hepatitis (ICVH), San Francisco, USA.
Stedman, C. (2016, August). Reaching for a cure for Hep C. Verbal presentation at the South General Practice Conference & Medical Exhibition (GP CME), Christchurch, New Zealand.
2015
Journal - Research Article
Foster, G. R., Afdhal, N., Roberts, S. K., Bräu, N., Gane, E. J., Pianko, S., … Stedman, C. A. M., … Sulkowski, M. (2015). Sofosbuvir and Velpatasvir for HCV genotype 2 and 3 infection. New England Journal of Medicine, 373(27), 2608-2617. doi: 10.1056/NEJMoa1512612
Pianko, S., Flamm, S. L., Shiffman, M. L., Kumar, S., Strasser, S. I., Dore, G. J., … Stedman, C. A. M., … Roberts, S. K. (2015). Sofosbuvir plus velpatasvir combination therapy for treatment: Experienced patients with genotype 1 or 3 hepatitis c virus infection: A randomized trial. Annals of Internal Medicine, 163(11), 809-817. doi: 10.7326/M15-1014
Naggie, S., Cooper, C., Saag, M., Workowski, K., Ruane, P., Towner, W. J., … Stedman, C. A. M., … for the ION-4 Investigators. (2015). Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. New England Journal of Medicine, 373(8), 705-713. doi: 10.1056/NEJMoa1501315
Gane, E. J., Hyland, R. H., An, D., Svarovskaia, E., Pang, P. S., Brainard, D., & Stedman, C. A. (2015). Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology, 149, 1454-1461. doi: 10.1053/j.gastro.2015.07.063
Gane, E., Kershenobich, D., Seguin-Devaux, C., Kristiansen, P., Aho, I., Dalgard, O., … Brunton, C. R., … Stedman, C., … Estes, C. (2015). Strategies to manage hepatitis C virus (HCV) infection disease burden: Volume 2. Journal of Viral Hepatitis, 22(Suppl. 1), 46-73. doi: 10.1111/jvh.12352
Saraswat, V., Norris, S., de Kneft, R. J., Sanchez Avila, J. F., Sonderup, M., Zuckerman, E., … Stedman, C., … Brunton, C. R., … Gower, E. (2015). Historical epidemiology of hepatitis C virus (HCV) in select countries: Volume 2. Journal of Viral Hepatitis, 22(Suppl. 1), 6-25. doi: 10.1111/jvh.12350
Hatzakis, A., Chulanov, V., Gadano, A. C., Bergin, C., Ben-Ari, Z., Mossong, J., … Brunton, C. R., … Stedman, C., … Razavi, H. (2015). The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm: Volume 2. Journal of Viral Hepatitis, 22(Suppl. 1), 26-45. doi: 10.1111/jvh.12351
Conference Contribution - Published proceedings: Abstract
Gane, E. J., Hyland, R. H., Yang, Y., Svarovskaia, E., Pang, P. S., McHutchison, J. G., & Stedman, C. A. (2015). Ledipasvir/sofosbuvir single tablet regimen is highly effective treatment for patients with HCV genotype 2 infection. Journal of Viral Hepatitis, 22(Suppl. 2), (pp. 15). doi: 10.1111/jvh.23_12424
Mangia, A., Roberts, S. K., Pianko, S., Thompson, A. J., Cooper, C., Conway, B., … Stedman, C. A., … Foster, G. R. (2015). Sofosbuvir/GS-5816 fixed dose combination for 12 weeks compared to sofosbuvir with ribavirin for 24 weeks in genotype 3 HCV infected patients: The randomised controlled phase 3 ASTRAL-3 study. Hepatology, 62(Suppl. 1), (pp. 338A). doi: 10.1002/hep.28207
Gane, E. J., Abergel, A., Metivier, S., Nahass, R., Ryan, M., & Stedman, C. A. (2015). The emergence of NS5B resistant associated variant S282T after sofosbuvir-based treatment. Hepatology, 62(Suppl. 1), (pp. 322A). doi: 10.1002/hep.28202
Gane, E. J., Hyland, R. H., Yang, Y., Stamm, L. M., Brainard, D. M., McHutchison, J. G., & Stedman, C. A. (2015). Sofosbuvir/GS-5816+GS-9857 for 6 or 8 weeks in genotype 1 or 3 HCV-infected patients. Hepatology, 62(Suppl. 1), (pp. 226A). doi: 10.1002/hep.28172
Conference Contribution - Verbal presentation and other Conference outputs
Stedman, C. (2015, November). Liver disease through pregnancy. Verbal presentation at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Section Annual Scientific Meeting, Rotorua, New Zealand.
Stedman, C. (2015, August). Hep B screening and surveillance in primary care. Workshop presentation at the South General Practice Conference & Medical Exhibition (GP CME), Christchurch, New Zealand.
Stedman, C. (2015, August). Eliminating Hep C from NZ. Plenary presentation at the South General Practice Conference & Medical Exhibition (GP CME), Christchurch, New Zealand.
Stedman, C. (2015, September). Hepatitis B and C. Invited presentation at the New Zealand Rheumatology Association Annual Scientific Meeting, Queenstown, New Zealand.
2014
Journal - Research Article
Gane, E., Stedman, C., Brunton, C., Radke, S., Henderson, C., Estes, C., & Razavi, H. (2014). Impact of improved treatment on disease burden of chronic hepatitis C in New Zealand. New Zealand Medical Journal, 127(1407). Retrieved from http://www.nzma.org.nz/journal
Stedman, C. (2014). Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: A review of its clinical potential. Therapeutic Advances in Gastroenterology, 7(3), 131-140. doi: 10.1177/1756283x13515825
Gane, E. J., Stedman, C. A., Hyland, R. H., Ding, X., Svarovskaia, E., Subramanian, G. M., … Pang, P. S. (2014). Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology, 146(3), 736-743. doi: 10.1053/j.gastro.2013.11.007
Conference Contribution - Published proceedings: Full paper
Kulkarni, R., Mauser-Bunschoten, E. P., Stedman, C., & Street, A. (2014). Medical co-morbidities and practice. Haemophilia, 20(Suppl. 4), (pp. 130-136). doi: 10.1111/hae.12403
Conference Contribution - Published proceedings: Abstract
Gane, E. J., Hyland, R. H., An, D., Svarovskaia, E. S., Pang, P. S., Symonds, W. T., … Stedman, C. A. (2014). High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection. Hepatology, 60(6, Suppl.), (pp. 1274A-1275A). doi: 10.1002/hep.27588
Gane, E. J., Brunton, C. R., Estes, C., Henderson, C., Hornell, J., Radke, S., … Stedman, C. A. (2014). Hepatitis C virus (HCV) infection in New Zealand: Burden of chronic disease. Hepatology, 60(4, Suppl.), (pp. 913A-914A). doi: 10.1002/hep.27525
Gane, E. J., Robson, R. A., Bonacini, M., Maliakkal, B., Liu, L., Sajwani, K., … Stedman, C. A., … Lawitz, E. (2014). Safety, anti-viral efficacy and pharmacokinetics (PK) of sofosbuvir (SOF) in patients with severe renal impairment. Hepatology, 60(4, Suppl.), (pp. 667A). doi: 10.1002/hep.27516
Gane, E. J., Hyland, R. H., An, D., McNally, J., Brainard, D. M., Symonds, W. T., … Stedman, C. A. (2014). Once daily sofosbuvir with GS-5816 for 8 weeks with or without ribavirin in patients with HCV genotype 3 without cirrhosis result in high rates of SVR12: The ELECTRON2 Study. Hepatology, 60(4, Suppl.), (pp. 236A-237A). doi: 10.1002/hep.27461
Gane, E., Hyland, R. H., Pang, P., Symonds, W. T., McHutchison, J. G., & Stedman, C. A. (2014). Sofosbuvir/ledipasvir fixed dose combination is safe and effective in HCV infected populations including decompensated patients and patients with prior sofosbuvir treatment experience. Gastroenterology, 146(5, Suppl. 1), (pp. S904-S905). doi: 10.1016/S0016-5085(14)63289-3
Svarovskaia, E. S., Martin, R., Gontcharova, V., Hyland, R. H., Gane, E. J., Stedman, C. A., … Mo, H. (2014). Resistance analysis of HCV genotype 1 infected patients treated with sofosbuvir in combination with ledipasvir or the NS5B nonnucleoside inhibitor GS-9669: The electron study. Journal of Hepatology, 60(1, Suppl.), (pp. S503). doi: 10.1016/S0168-8278(14)61402-1
Gane, E., Stedman, C., Garg, V., George, S., Kieffer, T., Krop, J., … Rubin, R. (2014). An interferon- and ribavirin-free 12-week regimen of once-daily VX-135 and daclatasvir in treatment-naive patients with genotype 1 HCV infection. Journal of Hepatology, 60(1, Suppl.), (pp. S528-S529). doi: 10.1016/S0168-8278(14)61470-7
Gane, E. J., Hyland, R. H., An, D., Pang, P. S., Symonds, W. T., McHutchison, J. G., & Stedman, C. A. (2014). Sofosbuvir/Ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior sofosbuvir treatment experience. Journal of Hepatology, 60(1, Suppl.), (pp. S3-S4). doi: 10.1016/S0168-8278(14)60008-8
Stedman, C. A., Hyland, R. H., Ding, X., Pang, P. S., Symonds, W. T., McHutchison, J. G., & Gane, E. J. (2014). Once daily sofosbuvir/ledipasvir fixed dose combination with RBV in patients with inherited bleeding disorders. Hepatology International, 8(1, Suppl.), (pp. S221). doi: 10.1007/s12072-014-9519-7
Gane, E. J., Hyland, R. H., Ding, X., An, D., Svarovskaia, E. S., Pang, P. S., … Stedman, C. A. (2014). Once daily sofosbuvir/ledipasvir fixed dose combination with or without RBV: The electron trials. Hepatology International, 8(1, Suppl.), (pp. S220). doi: 10.1007/s12072-014-9519-7
Gane, E. J., Rouzier, R., Hassanein, T., Stedman, C. A., Mazur, W., Kupcova, V., … Scalori, A. (2014). High rates of SVR24 in G1/4 patients with compensated cirrhosis, treated with a triple regimen of danoprevir/r + PegIFNα-2a/RBV (treatment naive), or with a quad regimen of danoprevir/r + mericitabine + PegIFNα-2a/RBV (previous null responders to PegIFN/RBV). Hepatology International, 8(1, Suppl.), (pp. S202-S203). doi: 10.1007/s12072-014-9519-7
Conference Contribution - Verbal presentation and other Conference outputs
Stedman, C. (2014, May). New approaches to hepatitis C management. Verbal presentation at the World Federation of Hemophilia (WFH) World Congress, Melbourne, Australia.
Stedman, C. (2014, August). Update on Hep B and Hep C. Verbal presentation at the South General Practice Conference & Medical Exhibition (GP CME), Dunedin, New Zealand.
Stedman, C. (2014, August). Community/GP based screening and management of HCV and HBV. Workshop presentation at the South General Practice Conference & Medical Exhibition (GP CME), Dunedin, New Zealand.
Stedman, C. (2014, June). Getting rid of Hep C in 2014. Workshop presentation at the General Practice Conference & Medical Exhibition (GP CME), Rotorua, New Zealand.
Stedman, C. (2014, June). Community/GP based screening and management of HBV and HCV. Workshop presentation at the General Practice Conference & Medical Exhibition (GP CME), Rotorua, New Zealand.
2013
Journal - Research Article
Ngu, J. H., Gearry, R. B., Frampton, C. M., & Stedman, C. A. M. (2013). Autoimmune hepatitis: The role of environmental risk factors: A population-based study. Hepatology International, 7(3), 869-875. doi: 10.1007/s12072-013-9448-x
Ngu, J. H., Wallace, M. C., Merriman, T. R., Gearry, R. B., Stedman, C. A. M., & Roberts, R. L. (2013). Association of the HLA locus and TNF with type I autoimmune hepatitis susceptibility in New Zealand Caucasians. SpringerPlus, 2(1), 355. doi: 10.1186/2193-1801-2-355
Ngu, J. H., Gearry, R. B., Frampton, C. M., & Stedman, C. A. M. (2013). Predictors of poor outcome in patients with autoimmune hepatitis: A population-based study. Hepatology, 57(6), 2399-2406. doi: 10.1002/hep.26290
Nishimura, T., Hu, Y., Wu, M., Pham, E., Suemizu, H., Elazar, M., … Stedman, C., … Peltz, G. (2013). Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interactions. Journal of Pharmacology & Experimental Therapeutics, 344(2), 388-396. doi: 10.1124/jpet.112.198697
Gane, E. J., Stedman, C. A., Hyland, R. H., Ding, X., Svarovskaia, E., Symonds, W. T., … Berrey, M. M. (2013). Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. New England Journal of Medicine, 368(1), 34-44. doi: 10.1056/NEJMoa1208953
Journal - Research Other
Stedman, C. A. M. (2013). Current prospects for interferon-free treatment of hepatitis C in 2012. Journal of Gastroenterology & Hepatology, 28(1), 38-45. doi: 10.1111/jgh.12028
Journal - Professional & Other Non-Research Articles
Ngu, J. H., Gearry, R. B., & Stedman, C. A. M. (2013). Mortality and the risk of malignancy in autoimmune liver diseases: A population-based study in Canterbury, New Zealand: Reply. Hepatology, 57(4), 1677-1678. doi: 10.1002/hep.25968
Conference Contribution - Published proceedings: Abstract
Gane, E. J., Stedman, C. A., Hyland, R. H., Ding, X., Pang, P. S., & Symonds, W. T. (2013). ELECTRON: 100% SVR rate for once-daily sofosbuvir plus ledipasvir plus ribavirin given for 12 weeks in treatment-naïve and previously treated patients with HCV GT 1. Proceedings of the 20th Conference on Retroviruses and Opportunistic Infections (CROI). Retrieved from http://www.natap.org/2013/CROI/croi_07.htm
Gane, E. J., Stedman, C. A., Hyland, R. H., Pang, P. S., Ding, X., Symonds, W. T., & McHutchison, J. G. (2013). All-oral sofobuvir-based 12-week regimens for the treatment of chronic HCV infection: The ELECTRON study. Journal of Hepatology, 58(Suppl. 1), (pp. S6-S7). [Abstract]
Conference Contribution - Poster Presentation (not in published proceedings)
Ngu, J. H., Wallace, M., Merriman, T., Gearry, R. B., Stedman, C. A. M., & Roberts, R. (2013, June). Association of the HLA locus and TNF with type I autoimmune hepatitis susceptibility in New Zealand Caucasians. Poster session presented at the Asian Pacific Association for the Study of the Liver (APASL) Liver Week, Singapore.
Ngu, J. H., Gearry, R. B., Frampton, C. M., & Stedman, C. A. M. (2013, June). Environmental risk factors in autoimmune hepatitis: A population-based case control study. Poster session presented at the Asian Pacific Association for the Study of the Liver (APASL) Liver Week, Singapore.
Conference Contribution - Verbal presentation and other Conference outputs
Stedman, C. (2013, November). Who to treat now and who to wait. Verbal presentation at the New Zealand Society of Gastroenterology & New Zealand Nurses Organisation Gastroenterology Section Annual Scientific Meeting, Wellington, New Zealand.
2012
Journal - Research Article
Chu, T. W., Kulkarni, R., Gane, E. J., Roberts, S. K., Stedman, C., Angus, P. W., … Shulman, N. S. (2012). Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology, 142(4), 790-795. doi: 10.1053/j.gastro.2011.12.057
Ngu, J. H., Gearry, R. B., Wright, A. J., & Stedman, C. A. M. (2012). Low incidence and prevalence of primary biliary cirrhosis in Canterbury, New Zealand: A population-based study. Hepatology International, 6(4), 796-800. doi: 10.1007/s12072-011-9329-0
Ngu, J. H., Gearry, R. B., Frampton, C. M., & Stedman, C. A. M. (2012). Mortality and the risk of malignancy in autoimmune liver diseases: A population-based study in Canterbury, New Zealand. Hepatology, 55(2), 522-529. doi: 10.1002/hep.24743
Journal - Research Other
Ngu, J. H., Gearry, R. B., & Stedman, C. A. M. (2012). Has primary sclerosing cholangitis associated with Crohn's disease a better outcome? Journal of Crohn's & Colitis, 6(9), 956. doi: 10.1016/j.crohns.2012.05.013
Journal - Professional & Other Non-Research Articles
Ngu, J. H., Gearry, R. B., & Stedman, C. A. M. (2012). [Reply to letter to the editor Primary sclerosing cholangitis: The gut-liver axis]. Clinical Gastroenterology & Hepatology, 10(7), 819-820. doi: 10.1016/j.cgh.2012.04.006
Conference Contribution - Published proceedings: Abstract
Ngu, J., Gearry, R., Frampton, C., & Stedman, C. (2012). Predictors of advanced liver fibrosis and poor outcome in patients with autoimmune hepatitis: A population-based study. Gut, 61(Suppl. 3), (pp. A230). [Abstract]
Gane, E., Stedman, C., Anderson, J., Hyland, R., Hindes, R., Symonds, W., & Berrey, M. M. (2012). GS-7977 + ribavirin in HCV genotype 1 null responders: Results from the ELECTRON trial. Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections (CROI). Retrieved from http://www.natap.org/2012/CROI/croi_07.htm
Ngu, J. H., Gearry, R. B., Frampton, C. M., & Stedman, C. A. M. (2012). Environmental risk factors in autoimmune hepatitis: A population-based case control study. New Zealand Medical Journal, 125(1367). Retrieved from http://www.nzma.org.nz/journal
Ngu, J. H., Gearry, R. B., Frampton, C. M., & Stedman, C. A. M. (2012). Predictors of poor outcome in patients with autoimmune hepatitis: A population-based study. New Zealand Medical Journal, 125(1367). Retrieved from http://www.nzma.org.nz/journal
2011
Journal - Research Article
Gane, E. J., Rouzier, R., Stedman, C., Wiercinska-Drapalo, A., Horban, A., Chang, L., … Tran, J. Q. (2011). Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients. Journal of Hepatology, 55, 972-979.
Ngu, J. H., Gearry, R. B., Wright, A. J., & Stedman, C. A. M. (2011). Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clinical Gastroenterology & Hepatology, 9(12), 1092-1097. doi: 10.1016/j.cgh.2011.08.027
Gardiner, S. J., Gearry, R. B., Burt, M. J., Chalmers-Watson, T., Chapman, B. A., Ross, A. G., Stedman, C. A. M., … Barclay, M. L. (2011). Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. Journal of Gastroenterology & Hepatology, 26(1), 49-54. doi: 10.1111/j.1440-1746.2010.06489.x
Conference Contribution - Published proceedings: Abstract
Tan, P. K., Stedman, C., & Orr, D. (2011). Portal venous thrombosis: Evaluation of long term follow up and determinants of survival. New Zealand Medical Journal, 124(1347). Retrieved from http://journal.nzma.org.nz/journal/124-1347/5015/content.pdf
Chu, T., Kulkarni, R., Gane, E. J., Roberts, S. K., Stedman, C., Angus, P., … Shulman, N. S. (2011). The effect of host IL28B genotype on early viral kinetics during interferon-free treatment in patients with chronic hepatitis C (CHC). Journal of Hepatology, 54(Suppl. 1), (pp. S521-S522). [Abstract]
Ngu, J. J., Gearry, R. B., Frampton, C. M., & Stedman, C. A. (2011). Mortality of autoimmune liver diseases in Canterbury, New Zealand: A population-based study. Gastroenterology, 140(5, Suppl. 1), (pp. S-906-S-907). [Abstract]
Ngu, J. J. H., Gearry, R., Frampton, C., & Stedman, C. (2011). Risk of malignancy in autoimmune liver diseases: A population-based study in Canterbury, New Zealand. Journal of Gastroenterology & Hepatology, 26(Suppl. 5), (pp. 170). doi: 10.1111/j.1440-1746.2011.06898.x
Gane, E. J., Stedman, C. A., Hyland, R. H., Sorensen, R. D., Symonds, W. T., Hindes, R., & Berrey, M. M. (2011). Once daily PSI-7977 plus RBV: Pegylated interferon-alfa not required for complete rapid viral response in treatment-naïve patients with HCV GT2 or GT3. Hepatology, 54(Suppl. 1), (pp. 377A). doi: 10.1002/hep.24666
Ngu, J. H., Gearry, R. B., & Stedman, C. A. M. (2011). Young age at diagnosis is a strong predictor of advanced liver fibrosis in patients with autoimmune hepatitis: A population-based study. New Zealand Medical Journal, 124(1347). Retrieved from http://journal.nzma.org.nz/journal/124-1347/5015/content.pdf
Ngu, J., Gearry, R., Frampton, C., & Stedman, C. (2011). Mortality of autoimmune liver diseases in Canterbury, New Zealand: A population-based study. Internal Medicine Journal, 41(Suppl. 2), (pp. 12-13). doi: 10.1111/j.1445-5994.2011.02486.x
Conference Contribution - Verbal presentation and other Conference outputs
Stedman, C. (2011, November). Triple therapy in Hepatitis C: Adding protease inhibitors to Peg/RBV in GT1. Verbal presentation at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting, Dunedin, New Zealand.
2010
Chapter in Book - Research
Stedman, C. A. M., Downes, M., & Liddle, C. (2010). Signaling pathways in liver disease: PXR and CAR. In J.-F. Dufour & P.-A. Clavien (Eds.), Signaling pathways in liver disease. (2nd ed.) (pp. 333-343). Berlin: Springer. doi: 10.1007/978-3-642-00150-5_22
Journal - Research Article
Gane, E. J., Roberts, S. K., Stedman, C. A. M., Angus, P. W., Ritchie, B., Elston, R., … Smith, P. F. (2010). Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): A randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet, 376(9751), 1467-1475. doi: 10.1016/s0140-6736(10)61384-0
Ngu, J. H., Bechly, K., Chapman, B. A., Burt, M. J., Barclay, M. L., Gearry, R. B., & Stedman, C. A. M. (2010). Population-based epidemiology study of autoimmune hepatitis: A disease of older women? Journal of Gastroenterology & Hepatology, 25(10), 1681-1686. doi: 10.1111/j.1440-1746.2010.06384.x
Conference Contribution - Published proceedings: Abstract
Ngu, J. H., Gearry, R. B., Frampton, C., & Stedman, C. A. M. (2010). Mortality of autoimmune liver diseases in Canterbury, New Zealand: A population-based study. New Zealand Medical Journal, 123(1327). Retrieved from http://journal.nzma.org.nz/journal/123-1327/4492/content.pdf
Ngu, J. H., Gearry, R. B., & Stedman, C. A. M. (2010). Survey of autoimmune hepatitis management in New Zealand. New Zealand Medical Journal, 123(1327). Retrieved from http://journal.nzma.org.nz/journal/123-1327/4492/content.pdf
Ngu, J. H., Wright, A., Gearry, R. B., Chapman, B. A., Burt, M. J., Barclay, M. L., & Stedman, C. A. M. (2010). Primary biliary cirrhosis in Canterbury, New Zealand: A population-based study. Journal of Gastroenterology and Hepatology. 25(Suppl. 2), (pp. A11). doi: 10.1111/j.1440-1746.2009.06462.x
Ngu, J. H., Wright, A., Gearry, R. B., Chapman, B. A., Burt, M. J., Barclay, M. L., & Stedman, C. A. M. (2010). Population-based epidemiology of primary sclerosing cholangitis in Canterbury, New Zealand. Journal of Gastroenterology and Hepatology. 25(Suppl. 2), (pp. A11). doi: 10.1111/j.1440-1746.2009.06462.x
Gane, E., Rouzier, R., Stedman, C., Wiercinska-Drapalo, A., Horban, A., Chang, L., … Tran, J. (2010). Ritonavir boosting of low dose RG7227/ITMN-191, HCV NS3/4A protease inhibitor, results in robust reduction in HCV RNA at lower exposures than provided by unboosted regimens. Journal of Hepatology. 52(Suppl. 1), (pp. S16-S17). [Abstract]
Gane, E., Foster, G. R., Cianciara, J., Stedman, C., Ryder, S., Buti, M., … Tait, D. (2010). Antiviral activity, pharmacokinetics, and tolerability of AZD7295, a novel NS5A inhibitor, in a placebo-controlled multiple ascending dose study in HCV genotype 1 and 3 patients. Journal of Hepatology. 52(Suppl. 1), (pp. S464). [Abstract]
Gane, E., Roberts, S., Stedman, C., Angus, P., Ritchie, B., Elston, R., … Smith, P. (2010). Early on-treatment responses during pegylated IFN plus ribavirin are increased following 13 days of combination nucleoside polymerase (RG7128) and protease (RG7227) inhibitor therapy (INFORM-1). Journal of Hepatology. 52(Suppl. 1), (pp. S291-S292). [Abstract]
2009
Journal - Research Article
Jonker, J. W., Stedman, C. A. M., Liddle, C., & Downes, M. (2009). Hepatobiliary ABC transporters: Physiology, regulation and implications for disease. Frontiers in Bioscience, 14, 4904-4920. doi: 10.2741/3576
Conference Contribution - Published proceedings: Abstract
Gane, E. J., Roberts, S. K., Stedman, C. A., Angus, P. W., Ritchie, B., Elston, R., … Smith, P. F. (2009). Combination therapy with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor in HCV: Safety, pharmacokinetics, and virologic results from INFORM-1. Hepatology. 50(4, Suppl.), (pp. S394-S395). [Abstract]
Gane, E. J., Roberts, S. K., Stedman, C., Angus, P. W., Ritchie, B., Elston, R., … Smith, P. F. (2009). First-in-man demonstration of potent anitviral activity with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor combination in HCV: Safety, pharmacokinetics, and virologic results from INFORM-1. Journal of Hepatology, 50(Suppl. 1), (pp. S380). doi: 10.1016/S0168-8278(09)61048-5
Conference Contribution - Poster Presentation (not in published proceedings)
Ngu, J. J. H., Wright, A., Gearry, R. B., Chapman, B. A., Burt, M. J., Barclay, M. L., & Stedman, C. A. M. (2009, November). Primary sclerosing cholangitis in Canterbury: High incidence and prevalence with reduced life expectancy. Poster session presented at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting, Wellington, New Zealand.
Conference Contribution - Verbal presentation and other Conference outputs
Ngu, J. J. H., Wright, A., Gearry, R. B., Chapman, B. A., Burt, M. J., Barclay, M. L., & Stedman, C. A. M. (2009, November). Population-based epidemiology of primary biliary cirrhosis in Canterbury, New Zealand. Verbal presentation at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting, Wellington, New Zealand.
Ngu, J. J. H., Bechly, K., Gearry, R. B., Chapman, B. A., Burt, M. J., Barclay, M. L., & Stedman, C. A. M. (2009, November). Population-based epidemiology study of autoimmune hepatitis: A disease of older women? Verbal presentation at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting, Wellington, New Zealand.
2008
Conference Contribution - Published proceedings: Abstract
Barclay, M. L., Gardiner, S. J., Gearry, R. B., Burt, M. J., Chalmers-Watson, T., Chapman, B. A., … Stedman, C. A. M. (2008). Allopurinol may improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. Journal of Gastroenterology and Hepatology. 23(Suppl. 4), (pp. A194). [Abstract]
Ngu, J. H., Bechly, K., Gearry, R. B., & Stedman, C. A. (2008). Epidemiology of autoimmune hepatitis in Canterbury, New Zealand: A retrospective population based-study. Hepatology. 48(4 (Suppl.)), (pp. 1094A-1095A). [Abstract]
Barclay, M. L., Gardiner, S. J., Gearry, R. B., Burt, M. J., Chalmers-Watson, T., Chapman, B. A., … Stedman, C. A. M. (2008). Allopurinol may improve response to azathioprine and 6-mercaptopurine by correcting an unfavourable metabolite ratio. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting. ASCEPT. Retrieved from http://phal.otago.ac.nz/ascept_docos/programme%202008.pdf
Conference Contribution - Verbal presentation and other Conference outputs
Stedman, C. (2008, March). A difficult case study. Verbal presentation at the 2nd New Zealand Viral Hepatitis Conference, Whakatane, New Zealand.
2007
Chapter in Book - Research
Liddle, C., & Stedman, C. A. M. (2007). Hepatic metabolism of drugs. In J. Rodes, J.-P. Benhamou, A. Blei, J. Reichen & M. Rizzetto (Eds.), Textbook of hepatology: From basic science to clinical practice. (3rd ed.) (pp. 241-249). Malden, MA: Blackwell.
Conference Contribution - Published proceedings: Abstract
Ngu, J. H., Bechly, K., Gearry, R. B., Chapman, B. A., Burt, M. J., Barclay, M. L., & Stedman, C. A. M. (2007). Prevalence of autoimmune hepatitis in Canterbury, New Zealand: A retrospective population based survey. New Zealand Medical Journal, 120(1266). Retrieved from http://journal.nzma.org.nz/journal/120-1266/2848/content.pdf
Conference Contribution - Verbal presentation and other Conference outputs
Stedman, C. (2007, November). Steatosis, obesity and treatment outcomes. Verbal presentation at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting combined with the RACP and IMSANZ, Christchurch, New Zealand.
Ngu, J. H., Bechly, K., Gearry, R. B., Chapman, B. A., Burt, M. J., Barclay, M. L., & Stedman, C. A. M. (2007, November). Prevalence of autoimmune hepatitis in Canterbury, New Zealand: A retrospective population based survey. Verbal presentation at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting combined with the RACP and IMSANZ, Christchurch, New Zealand.
Commissioned Report for External Body
Gane, E., Stedman, C., Kyle, C., & Whittaker, N. (2007). Liver function testing in primary care. Dunedin, New Zealand: bpac. 31p.
2006
Journal - Research Article
Stedman, C., Liddle, C., Coulter, S., Sonoda, J., Alvarez, J. G., Evans, R. M., & Downes, M. (2006). Benefit of farnesoid X receptor inhibition in obstructive cholestasis. PNAS, 103(30), 11323-11328.
Awarded Doctoral Degree
Stedman, C. A. M. (2006). Role of nuclear receptors in bile acid disposition and detoxification (PhD). University of Sydney, Sydney, Australia. 129p.
2005
Journal - Research Article
Stedman, C. A. M., Liddle, C., Coulter, S. A., Sonoda, J., Alvarez, J. G. A., Moore, D. D., … Downes, M. (2005). Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. PNAS, 102(6), 2063-2068.
Conference Contribution - Published proceedings: Abstract
Stedman, C. A. M., Liddle, C., Coulter, S., Evans, R., & Downes, M. (2005). Multiple targeting of nuclear receptors ameliorates acute cholestatic liver injury. Journal of Gastroenterology & Hepatology, 20(Suppl. 1), (pp. A76). doi: 10.1111/j.1440-1746.2005.04091_4.x
Stedman, C., Liddle, C., Coulter, S., Evans, R., & Downes, M. (2005). Multiple targeting of nuclear receptors ameliorates acute cholestatic liver injury. Hepatology. 42(4, Suppl. 1), (pp. 509A). [Abstract]
Conference Contribution - Verbal presentation and other Conference outputs
Stedman, C. A. M., Coulter, S., Liddle, C., Evans, R., & Downes, M. (2005, November). Acute cholestatic liver injury is ameliorated by targeting of multiple nuclear receptors. Verbal presentation at the Annual Scientific Meeting of the New Zealand Society of Gastroenterology and NZNO Gastroenterology Nurses' Section, Hamilton, New Zealand.
2004
Journal - Research Article
Stedman, C., Robertson, G., Coulter, S., & Liddle, C. (2004). Feed-forward regulation of bile acid detoxification by CYP3A4. Journal of Biological Chemistry, 279(12), 11336-11343.
Conference Contribution - Published proceedings: Abstract
Stedman, C. A. M., Coulter, S., Liddle, C., Evans, R., & Downes, M. (2004). Nuclear receptor modulation of hepatic injury in acute cholestasis. Clinical and Experimental Pharmacology and Physiology. 31(Suppl.), (pp. A143). [Abstract]
2003
Conference Contribution - Poster Presentation (not in published proceedings)
Stedman, C., Robertson, G., Coulter, S., & Liddle, C. (2003, May). Feed-forward regulation of bile acid detoxification by CYP3A4: Studies in humanized transgenic mice. Poster session presented at the The American Association for the Study of Liver Diseases: The Henry M. and Lillian Stratton Basic Research Single Topic Conference, Warrenton, Virginia, USA.
Conference Contribution - Verbal presentation and other Conference outputs
Stedman, C., Robertson, G., Coulter, S., & Liddle, C. (2003, September). Feed-forward regulation of bile acid detoxification by CYP3A4: Studies in humanized transgenic mice. Verbal presentation at the New Zealand Society of Gastroenterology and NZNO Gastroenterology Nurses' Section Annual Scientific Meeting, Queenstown, New Zealand.
2002
Journal - Research Article
Stedman, C. (2002). Herbal hepatotoxicity. Seminars in Liver Disease, 22(2), 195-206.
Stedman, C. A. M., Begg, E. J., Kennedy, M. A., Roberts, R., & Wilkinson, T. J. (2002). Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia. Human Psychopharmacology, 17(4), 187-190.
Conference Contribution - Published proceedings: Abstract
Stedman, C., Lehnert, A., Robertson, G., & Liddle, C. (2002). cDNA microarray analysis of gene expression in acute cholestasis after bile duct ligation. Journal of Gastroenterology and Hepatology. 17(Suppl.), (pp. A160). [Abstract]
Stedman, C., Robertson, G., Field, J., & Liddle, C. (2002). Which bile acids invoke hepatic adaptive responses in acute cholestasis? Journal of Gastroenterology and Hepatology. 17(Suppl.), (pp. A158). [Abstract]
Conference Contribution - Verbal presentation and other Conference outputs
Stedman, C. (2002, November). Changes in gene expression after acute cholestasis: cDNA microarray analysis. Verbal presentation at the New Zealand Society of Gastroenterology and NZNO Gastroenterology Nurses' Section Annual Scientific Meeting, Auckland, New Zealand.
2001
Conference Contribution - Published proceedings: Abstract
Stedman, C. A., Robertson, G., Field, J., & Liddle, C. (2001). Hepatoprotective response to cholestasis: Bile duct ligation activates transcription of a human CYP3A4/LACZ transgene in mice. Hepatology. 34(4), (pp. 469A). [Abstract]
Stedman, C., Robertson, G., Field, J., & Liddle, C. (2001). Hepatoprotective response to cholestasis: Bile duct ligation activates transcription of a human CYP3A4/LACZ transgene in mice. Journal of Gastroenterology and Hepatology. 16(Suppl.), (pp. A67). [Abstract]
2000
Journal - Research Other
Stedman, C. A. M., & Barclay, M. L. (2000). Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Alimentary Pharmacology & Therapeutics, 14(8), 963-978. doi: 10.1046/j.1365-2036.2000.00788.x